Role of presensitization and donor-recipient crossmatching in corneal graft outcome.
OBJECTIVE
A positive donor-recipient crossmatch (CM) due to preexisting recipient lymphocytotoxic antibodies is known to be an important factor in allograft failure in the majority of organ transplantations. However, the effect of positive CM on corneal graft outcome is less known.


METHODS
Between 1982 and 1994, CM was performed by the microlymphocytotoxicity method using donor lymphocytes and recipient pretransplant serum in 759 consecutive corneal transplantations (maximal follow-up, 36 months). Patients were evaluated regarding the type of allospecificity of antibodies involved and their role on corneal graft outcome (rejection and failure).


RESULTS
A positive CM was found in 61 patients (8%) and a negative CM in 698 patients (92%). The positive and negative CM groups had similar graft rejection rates at 36 months. Patients with a positive CM due to antibodies directed against donor human leukocyte antigen (HLA) (as defined on the basis of private and public or CREG HLA allele specificities) did not have an increased risk of rejection. However, patients with positive CM and presensitization (previous graft or rejection history) had a statistically significant increase in risk of corneal endothelial rejection.


CONCLUSIONS
This study shows that donor-recipient CM could be a useful procedure for the selection of recipients for corneal transplantation in patients presensitized by anterior graft or previous corneal rejection.
Des Marchais
B
B
Centre de Recherche en Rhumatologie-Immunologie, Centre Hospitalier Universitaire de Québec, Ste-Foy, Canada.
Bazin
R
R
Boisjoly
H M
HM
Laughrea
P A
PA
Dubé
I
I
Lille
S
S
Roy
R
R
D000328:Adult; D000483:Alleles; D003315:Cornea / Q000276:immunology*; D016039:Corneal Transplantation / Q000276:immunology*; D003601:Cytotoxicity Tests, Immunologic; D006084:Graft Rejection / Q000276:immunology; D006085:Graft Survival / Q000276:immunology; D006680:HLA Antigens / Q000276:immunology*; D006650:Histocompatibility Testing; D006801:Humans; D007114:Immunization; D007518:Isoantibodies / Q000032:analysis; D014019:Tissue Donors; D016896:Treatment Outcome
D006680:HLA Antigens; D007518:Isoantibodies